Identification of a C3’-nitrile nucleoside analogue inhibitor of pancreatic cancer cell line growth

Abstract A synthetic strategy to access a novel family of nucleoside analogues bearing a C3’-nitrile substituted all-carbon quaternary center is presented herein. These purine bearing scaffolds were tested in two pancreatic cancer cell lines harboring either wild-type (BxPC3) or G12V KRAS (Capan2) mutations. A promising compound was shown to have significantly greater efficacy in the Capan2 cell line as compared to Gemcitabine, the clinical gold standard used to treat pancreatic cancer.